13F filing recap · Q1 2018

What did Chou Associates buy in Q1 2018?

Reported stock-position changes between this filing and the previous one.

Stock value

$232.57M

Positions

Estimated turnover

12.4%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Increased positions

VRXValeant Pharmaceuticals International, Inc.$26.25Mreported value+1.50M shares+1006.8%ENDPEndo International Plc$5.23Mreported value+800.0K shares+1000.0%